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Abstract: Post-transplant diabetes mellitus (PTDM) is a serious complication in renal transplant
recipients. Branched-chain amino acids (BCAAs) are involved in the pathogenesis of insulin resistance.
We determined the association of plasma BCAAs with PTDM and included adult renal transplant
recipients (≥18 y) with a functioning graft for ≥1 year in this cross-sectional cohort study with
prospective follow-up. Plasma BCAAs were measured in 518 subjects using nuclear magnetic
resonance spectroscopy. We excluded subjects with a history of diabetes, leaving 368 non-diabetic
renal transplant recipients eligible for analyses. Cox proportional hazards analyses were used to
assess the association of BCAAs with the development of PTDM. Mean age was 51.1 ± 13.6 y (53.6%
men) and plasma BCAA was 377.6 ± 82.5 µM. During median follow-up of 5.3 (IQR, 4.2–6.0) y,
38 (9.8%) patients developed PTDM. BCAAs were associated with a higher risk of developing PTDM
(HR: 1.43, 95% CI 1.08–1.89) per SD change (p = 0.01), independent of age and sex. Adjustment
for other potential confounders did not significantly change this association, although adjustment
for HbA1c eliminated it. The association was mediated to a considerable extent (53%) by HbA1c.
The association was also modified by HbA1c; BCAAs were only associated with renal transplant
recipients without prediabetes (HbA1c < 5.7%). In conclusion, high concentrations of plasma BCAAs
are associated with developing PTDM in renal transplant recipients. Alterations in BCAAs may
represent an early predictive biomarker for PTDM.
Keywords: branched chain amino acids; post-transplant diabetes mellitus; biomarker; renal
transplant recipients
1. Introduction
Post-transplant diabetes after transplantation (PTDM), often a result of insulin resistance and
deficient insulin production [1], is a serious complication in renal transplant recipients [2]. PTDM
develops in 10–20% of renal transplant recipients during the first year post-transplantation [3],
although some studies reported incidences of up to 50% [4]. PTDM is an important risk factor for
cardiovascular disease (CVD) and infections, contributing to impaired graft and patient survival [5–7].
Previous studies have shown that PTDM is an important risk factor for premature mortality in renal
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transplant recipients [8–10]. Since the main cause of death in these patients is cardiovascular-related [11–13]
and most of these patients die with a properly functioning graft [14], it is clinically relevant to identify
patients that are at high risk of developing PTDM.
Non-modifiable risk factors for the development of PTDM are patient’s age, race, genetic
background, and family history of diabetes. On the other hand, modifiable risk factors include
overweight and obesity, but also immunosuppressive medication, such as steroids and calcineurin
inhibitors [5]. During the era of cyclosporine-based regimens, the largest number of incident cases
of PTDM occurred beyond the first year after transplantation [2] and with current tacrolimus-based
regimens, the number of incident cases of PTDM beyond the first year after transplantation is even
higher [15]. Furthermore, it should be noted that if a renal transplant recipient is diagnosed with
diabetes, it is considered PTDM, irrespective whether this occurs one-year post-transplantation or
10 years later [16].
Current research is focused on a better understanding of risk factors responsible for the
development of PTDM. Branched chain amino acids (BCAAs), a group of three essential amino
acids (i.e., valine, leucine, and isoleucine), can be obtained from diet and comprise about 15–25%
of total protein intake [17]. BCAAs not only play an important role in protein metabolism,
but also have metabolic functions [18]. They may stimulate protein synthesis and influence glucose
homeostasis [19–21]. It is known that circulating concentrations of BCAAs are elevated in subjects
with prediabetes, type 2 diabetes, metabolic syndrome, and obesity [20,22,23]. Previous studies have
assessed the association of BCAAs with insulin resistance and development of type 2 diabetes [24,25].
Recently, we reported that high concentrations of BCAAs are associated with an increased risk of
developing type 2 diabetes in a large prospective cohort study in the general population [26]. High
concentrations of BCAAs might be the consequence of excess dietary consumption, dysbiosis of the
gut microbiota, and reduced breakdown of BCAAs in skeletal muscle and adipose tissue [20,23,27,28].
It has been found that kidney transplant recipients suffer from dysbiosis of gut microbiota [29,30].
Chronic use of immunosuppressive medication, including glucocorticoids and calcineurin inhibitors,
by kidney transplant recipients is moreover likely to influence skeletal muscle metabolism [31,32].
These factors could alter BCAAs in kidney transplant recipients compared to the general population
and thereby contribute to development of diabetes.
Previous population-based studies have shown inverse associations between BCAAs and all-cause
mortality [33–35]. Furthermore, it is known that disturbances in amino acid metabolism, particularly
involving BCAAs, occur in patients with end-stage renal disease [36]. A previous study showed that
levels of valine and leucine, but not isoleucine, were significantly lower in patients with stage I and II
chronic kidney when compared to controls [37].
Whether BCAA plasma concentrations are associated with development of PTDM in renal
transplant recipients has not yet been established. Therefore, we hypothesized that higher plasma
BCAA concentrations are associated with a higher risk of developing PTDM in renal transplant
recipients, as a primary endpoint. Furthermore, secondary endpoints of this study were all-cause
mortality and death-censored graft failure, because these endpoints could potentially compete with
development of PTDM as an endpoint.
2. Materials and Methods
2.1. Study Design and Population
In this large cross-sectional study with prospective follow-up, we included stable adult renal
transplant recipients (≥18 y) with a functioning graft for at least one year after transplantation
(i.e., on maintenance immunosuppression and with a stable renal function), therefore excluding
patients with transient hyperglycemia post-transplantation. Between November 2008 and May
2011, patients who visited the outpatient clinic of the University Medical Center Groningen were
invited to participate. Both subjects with known or apparent systemic diseases (i.e., malignancies,
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opportunistic infections) and subjects with a history of alcohol and/or drug addiction were excluded
from participation. Informed consent was given by 707 (86.5%) of 817 initially invited patients. We
excluded patients with missing data on BCAA, resulting in 518 renal transplant recipients eligible for
analyses. As previously described, we recorded age, sex, body composition and eGFR of the renal
transplant recipients who did not consent [38]. Compared with participating renal transplant recipients,
those who did not consent were slightly older (mean age ± SD, 58 ± 13 years versus 53 ± 13 years)
and had lower eGFR (47 ± 19 ml/min per 1.73 m2 versus 51 ± 20 ml/min per 1.73 m2) [38]. For the
analyses with PTDM, we also excluded patients with diabetes or a history of diabetes at baseline
(n = 132). Of these 132 renal transplant recipients, 34 were diagnosed with diabetes before renal
transplantation and 98 developed PTDM between time of transplantation and baseline, leaving 386
renal transplant recipients eligible for analyses (Supplementary Figure S1). The study protocol was
approved by the institutional research board (METc 2008/186), which adheres to the Principles of the
Declaration of Helsinki.
2.2. Data Collection
During a morning visit to the outpatient clinic, all baseline data were collected as described
previously [39]. Body weight and height were measured. Body Mass Index (BMI) was calculated
as weight in kilograms divided by height in meters squared (kg/m2). Systolic and diastolic blood
pressure and heart rate were measured every minute for 15 minutes in a half-sitting position using a
semi-automatic device (Dinamap®1846; Critikon, Tampa, FL, USA) to prevent white coat effects [40].
The average of the last three measurements was taken as blood pressure value. Information on
medication was derived from patient records, whereas information on smoking behavior was obtained
by questionnaire. Information on physical activity was obtained using the reliable and valid Short
Questionnaire to Assess Health enhancing physical activity (SQUASH) score in time multiplied by
intensity [41]. Alcohol consumption and total energy intake were measured using a reproducible,
validated food frequency questionnaire (FFQ) [42], which consisted of 177 items and was updated
several times. Blood samples were taken after an 8–12 h overnight fasting period in the morning after
completion of 24 h urine collection. Renal transplant recipients were instructed to assure adequate
urine collection. They were instructed to discard their first morning urine specimen and then collect
their urine for the next 24 h, including the next morning’s first specimen the day of their visit. Protein
intake was measured using 24 h urinary urea excretion. Estimated Glomerular Filtration Rate (eGFR)
was calculated using the serum creatinine-based Chronic Kidney Disease Epidemiology Collaboration
equation [43].
2.3. Quantification of BCAAs
Plasma BCAA concentrations were measured at baseline using a Vantera Clinical Analyzer
(LabCorp, Morrisville, NC, USA), a fully automated, high-throughput, 400 MHz proton (1H) nuclear
magnetic resonance spectroscopy (NMR) platform. Quantification of BCAAs by NMR was validated
and had been previously described in detail elsewhere [25,44]. The within-laboratory (inter-assay) and
within-run (intra-assay) imprecision for NMR-measured BCAAs are described in detail previously [44].
For total BCAAs, the coefficients of variation for inter-assay and intra-assay were 1.8–6.0% and
2.1–4.4%, respectively.
2.4. Clinical Endpoints
The primary outcome of this study was PTDM, which was defined as at least one of the following
criteria: symptoms of diabetes (e.g., polyuria, polydipsia, unexplained weight loss) plus a non-fasting
plasma glucose concentration of ≥200mg/dL (11.1 mmol/L); fasting plasma glucose concentration (FPG)
≥126 mg/dL (7.0 mmol/L); start of antidiabetic medication; or HbA1c≥6.5% (48 mmol/L). This definition
was according to the American Diabetes Association criteria for diabetes [45], including HbA1c levels
as proposed by the International Expert Panel of the international consensus meeting on PTDM [46].
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The secondary outcomes of this study were all-cause mortality and death-censored graft failure.
Death-censored graft failure was defined as return to hemodialysis treatment or retransplantation.
All subjects received medical care at the University Medical Center Groningen alone or medical care
shared with a secondary referral hospital. In accordance with the KDIGO guideline for renal transplant
recipients, follow-up visits after the first year post transplantation were performed every 3 months [47].
Data on PTDM, all-cause mortality and death-censored graft failure were retrieved from patient files
and verified with the corresponding nephrologist or the Municipal Personal Records Database in case
of death. Endpoints were recorded until the end of September 2015. Since the outpatient program uses
continuous surveillance systems, it guarantees correct and up-to-date information on patient status.
No participants were lost to follow-up.
2.5. Statisical Analyses
Normal distributed data were presented as mean and standard deviation, whereas skewed
distributed data were expressed as median and interquartile range. Categorical data were presented as
number and percentage. Differences between diabetic and non-diabetic renal transplant recipients
were compared using unpaired t-tests for normally distributed variables, Mann–Whitney U tests
for skewed distributed variables and Chi-square tests for categorical variables. Differences between
tertiles of total BCAA were compared using one-way ANOVA tests for normally distributed variables,
Kruskal–Wallis tests for skewed distributed variables and Chi-square tests for categorical variables.
Skewed distributed data were log-transformed when appropriate. Correlations between BCAAs
and total energy intake, protein intake, physical activity, and HbA1c in non-diabetic renal transplant
recipients were assessed using Pearson correlation coefficients.
Kaplan–Meier curves were plotted for the development of PTDM according to the highest
tertile versus the two lowest tertiles of total BCAA. We performed crude and multivariable Cox
proportional hazards regression analyses to assess the association of total BCAA with the development
of PTDM. First, we performed crude analyses and analyses adjusted for age and sex (model 1). We
further cumulatively adjusted for renal function parameters (eGFR, proteinuria, and time between
transplantation and baseline) in model 2. To prevent overfitting by including too many covariates in
relation to number of events [48], we adjusted for other potential confounders in additional models
based on model 2. We additionally adjusted for total cholesterol and triglycerides in model 3; total
energy intake, physical activity, and BMI in model 4; smoking status and alcohol consumption in
model 5; prednisolone dose and trough levels of tacrolimus and cyclosporine in model 6. Total BCAA
per 1 standard deviation (SD) was used as continuous variable, but also as categorical variable (highest
tertile versus two lowest tertiles). Patients were censored at date of last follow-up or death. Hazards
ratios and 95% CIs were given for the Cox proportional hazards analyses. Schoenfeld residuals of
the BCAAs were checked and tested in STATA using the proportional hazard test by Grambsch and
Therneau [49]. Furthermore, penalized splines analyses performed in R were used to visualize the
association of total BCAA with the development of PTDM, adjusted for age and sex. Additionally, we
evaluated potential effect modification by age, gender, BMI, eGFR and HbA1c by entering both main
effects and the cross-product term in the crude model. When effect modification was observed, we
proceeded with stratified analyses, with a HbA1c of 5.7–6.4% considered as prediabetic state [50,51].
In further analyses, we investigated whether plasma glucose and HbA1c could serve as mediator
in the association of BCAAs and risk of PTDM. To investigate potential mediation, we performed
mediation analyses using the mediation package of R [52], by which we tested significance and
magnitude of mediation (see the Supplementary Materials for a detailed description). Competing risks
occur when patients can experience or develop one or more events which compete with the outcome
of interest [53]. To rule out competing risk of all-cause mortality with the development of PTDM,
we performed competing risk analyses according to Fine and Gray [54]. We performed crude and
multivariable Cox proportional hazards regression analyses to assess the association of total BCAA
with the secondary outcomes all-cause mortality and death-censored graft failure. Total BCAA per
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1 standard deviation (SD) was used as continuous variable, but also as categorical variable (lowest
tertile versus two highest tertiles). For the association of BCAAs with both all-cause mortality and
death-censored graft failure, we evaluated the potential effect modification by diabetes.
A two-sided p-value of <0.05 was considered statistically significant. The main statistical analyses
for the manuscript were performed using IBM Statistics SPSS version 23.0 (IBM Inc, Chicago, IL, USA).
We used STATA version 11.0 (StataCorp LP, College Station, TX, USA) to check and test the Schoenfeld
residuals by performing the proportional hazard test according to Grambsch and Therneau. We used
R version 3.2.3 (R Foundation for Statistical Computing, Vienna, Austria) to perform penalized splines
analyses and to perform mediation analyses. We used GraphPad Prism 5 (GraphPad Software Inc., La
Jolla, CA, USA) to visualize the Kaplan–Meier curves for the development of PTDM.
3. Results
3.1. Patient Characteristics in Whole Cohort (n = 518)
Mean age of overall renal transplant recipients was 52.7 ± 13.0 y and 53.7% of the participants were
men. Median time between baseline measurements and transplantation was 5.0 (IQR, 1.7–11.9) years.
Diabetic renal transplant recipients had significantly higher plasma concentrations of total BCAA
(424.6 ± 97.9 µM) when compared with non-diabetic renal transplant recipients (377.6 ± 82.5 µM).
Baseline characteristics of the overall (n = 518), diabetic (n = 132) and non-diabetic (n = 386) population
are shown in Table 1. Non-diabetic subjects were younger, had a lower weight and BMI, had a
higher physical activity score and lower heart rate when compared with diabetic RTR. Furthermore,
non-diabetic subjects had lower plasma glucose, HbA1c, and triglycerides, and higher HDL cholesterol
concentrations. No differences were seen in medication, except for use of statins, which was more
common in the diabetic renal transplant recipients than in the non-diabetic renal transplant recipients.
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Table 1. Baseline characteristics in renal transplant recipients (n = 518).
Total (n = 518) Diabetic RTR (n = 132) Non-Diabetic RTR (n = 386) P-Value
General characteristics
Age, years 52.7 ± 13.0 57.2 ± 10.1 51.1 ± 13.6 <0.001
Male sex, n (%) 278 (53.7) 71 (46.2) 207 (53.6) 0.97
Race (white), n (%) 515 (99.4) 132 (100.0) 383 (99.2) 0.31
BMI, kg/m2 26.6 ± 4.8 28.7 ± 5.3 25.9 ± 4.5 <0.001
Physical activity score
(time x intensity) 5075 (2190–8100) 3690 (1215–6563) 5590 (2810–8715) <0.001
Smoking status, n (%) 0.16
Never 203 (39.2) 49 (37.1) 154 (39.9)
Former 228 (44.0) 63 (47.7) 165 (42.7)
Current 63 (12.2) 10 (7.6) 53 (13.7)
Alcohol consumption, g/d 2.3 (0.0–11.1) 1.6 (0.0–7.4) 2.6 (0.0–11.7) 0.05
Total energy intake, kcal/d 2139 ± 634 2106 ± 599 2152 ± 647 0.49
Urea excretion, mmol/24h 389.4 ± 117.2 391.2 ± 124.3 388.8 ± 114.9 0.83
Circulation
Heart rate, b.p.m. 68.6 ± 12.1 72.2 ± 11.3 67.3 ± 12.1 <0.001
SBP, mmHg 135.9 ± 17.7 138.2 ± 18.5 135.1 ± 17.4 0.07
DBP, mmHg 82.1 ± 11.0 82.0 ± 10.3 82.1 ± 11.3 0.93
Transplant characteristics
Transplant vintage, years 5.0 (1.7–11.9) 6.2 (1.7–11.8) 4.9 (1.7–12.0) 0.59
Living donor, n (%) 182 (35.1) 37 (28.0) 145 (37.6) 0.05
Pre-emptive transplant, n (%) 91 (17.6) 14 (10.6) 77 (19.9) 0.02
Dialysis duration, months 42.0 (18.5–59.0) 36.0 (18.5–52.5) 44.0 (17.0–59.8) 0.58
Age donor, years 43.7 ± 15.2 41.9 ± 15.2 44.3 ± 15.2 0.12
Renal allograft function
Serum creatinine, µmol/L 127.0 (101.0–167.3) 133.0 (102.3–166.0) 126.0 (101.0–168.0) 0.77
eGFR, ml/min per 1.73 m2 50.6 ± 19.9 49.5 ± 20.8 51.0 ± 19.6 0.45
Proteinuria, n (%) 117 (22.6) 35 (26.5) 82 (21.2) 0.19
Glucose homeostasis
Plasma glucose (mmol/L) 5.2 (4.8–6.0) 7.0 (5.4–8.1) 5.1 (4.7–5.5) <0.001
HbA1c (%) 6.0 ± 0.8 6.9 ± 1.1 5.7 ± 0.4 <0.001
Lipids and lipoproteins
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Table 1. Cont.
Total (n = 518) Diabetic RTR (n = 132) Non-Diabetic RTR (n = 386) P-Value
Total cholesterol, mmol/L 5.2 ± 1.2 5.2 ± 1.2 5.1 ± 1.1 0.64
HDL-cholesterol, mmol/L 1.4 ± 0.5 1.3 ± 0.4 1.4 ± 0.5 0.03
LDL-cholesterol, mmol/L 3.0 ± 0.9 3.0 ± 1.0 3.0 ± 0.9 0.59
Triglycerides, mmol/L 1.7 (1.3–2.4) 1.9 (1.4–3.0) 1.7 (1.2–2.2) <0.001
Medication
Calcineurin inhibitor, n (%) 0.19
Cyclosporine 218 (42.1) 61 (46.2) 157 (40.7)
Tacrolimus 93 (18.0) 27 (20.5) 66 (17.1)
Trough level cyclosporine (µg/L) 108.0 (77.0–144.0) 102.5 (74.0–156.0) 111.0 (77.5–142.0) 0.78
Trough level tacrolimus (µg/L) 6.8 (5.0–9.0) 6.6 (5.4–9.9) 7.2 (4.9–9.0) 0.78
Proliferation inhibitor, n (%) 0.20
Azathioprine 100 (19.3) 22 (16.7) 78 (20.2)
Mycofenol 333 (64.3) 82 (62.1) 251 (65.0)
Prednisolone, n (%) 513 (99.0) 131 (99.2) 382 (99.0) 0.78
Prednisolone dose, mg/24h 10.0 (7.5–10.0) 10.0 (7.5–10.0) 10.0 (7.5–10.0) 0.71
Antihypertensive drugs, n (%) 462 (89.2) 121 (91.7) 341 (88.3) 0.29
Statins, n (%) 270 (52.1) 84 (63.6) 186 (48.2) 0.002
Amino acids
Total BCAA, µM 389.6 ± 89.0 424.6 ± 97.9 377.6 ± 82.5 <0.001
Valine, µM 203.0 ± 44.7 217.0 ± 48.9 198.2 ± 42.2 <0.001
Leucine, µM 141.7 ± 37.3 157.1 ± 42.1 136.5 ± 34.0 <0.001
Isoleucine, µM 44.9 ± 19.1 51.8 ± 20.0 43.5 ± 17.8 <0.001
Data are represented as mean ± SD, median (interquartile range) or n (%). Differences were tested by unpaired T-test or Mann–Whitney U test for continuous variables and with χ 2-test for
categorical variables. RTR, renal transplant recipients; SBP, systolic blood pressure; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HbA1c, hemoglobin A1c;
LP-IR, lipoprotein insulin resistance index; HDL, high-density lipoprotein; LDL, low-density lipoprotein; BCAA, branched-chain amino acids.
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3.2. Patient Characteristics in Subgroup of Non-Diabetic Renal Transplant Recipients (n = 386)
For the non-diabetic renal transplant recipients the baseline characteristics according to tertiles of
total BCAAs are presented in Table 2. Subjects in the highest tertile of total BCAA were more often
male, consumed more alcohol, had a lower heart rate, and a lower HDL cholesterol when compared
with subjects in the lowest tertile. There were no differences in transplant characteristics, renal allograft
function, and glucose homeostasis. Furthermore, we found that total BCAAs were positively correlated
with protein intake (r = 0.25, p = <0.001) and HbA1c (r = 0.12, p = 0.02), but not with total energy
intake (r = –0.01, p = 0.82) and physical activity (r = 0.10, p = 0.06). When we divided the non-diabetic
renal transplant recipients in patients with prediabetes (HbA1c ≥ 5.7%) and without prediabetes
(HbA1c < 5.7%), we found a positive correlation in the prediabetic renal transplant recipients (r = 0.23,
p = 0.002), but not in renal transplant recipients without prediabetes (r = 0.003, p = 0.96).
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Table 2. Baseline characteristics of non-diabetic renal transplant recipients according to tertiles of total BCAA (n = 386).
Tertile 1 (n = 127) Tertile 2 (n = 130) Tertile 3 (n = 129) P-Value
General characteristics
Age, years 49.9 ± 13.3 52.8 ± 14.4 50.6 ± 12.9 0.19
Male sex, n (%) 81 (63.8) 73 (56.2) 88 (68.2) <0.001
Race (white), n (%) 126 (99.2) 129 (99.2) 128 (99.2) 1.00
BMI, kg/m2 25.4 ± 5.2 26.0 ± 4.2 26.3 ± 3.9 0.27
Physical activity score
(time x intensity) 4930 (2100–7260) 5905 (3315–8625) 6100 (3120–9860) 0.05
Smoking status, n (%) 0.10
Never 54 (42.5) 58 (44.6) 42 (32.6)
Former 47 (37.0) 51 (39.2) 67 (51.9)
Current 21 (16.5) 17 (13.1) 15 (11.6)
Alcohol consumption, g/d 1.6 (0.0–8.9) 2.9 (0.1–11.3) 4.3 (0.1–15.8) 0.03
Total energy intake, kcal/d 2178 ± 631 2184 ± 724 2096 ± 578 0.51
Urea excretion, mmol/24h 335.1 ± 92.5 406.6 ± 117.2 423.2 ± 114.2 <0.001
Circulation
Heart rate, b.p.m. 70.3 ± 12.3 66.0 ± 12.5 65.8 ± 11.0 0.005
SBP, mmHg 134.9 ± 17.8 133.9 ± 18.2 136.4 ± 16.1 0.51
DBP, mmHg 81.7 ± 11.8 80.4 ± 11.4 84.1 ± 10.4 0.03
Transplant characteristics
Transplant vintage, years 5.0 (1.8–14.9) 4.7 (1.7–12.0) 4.9 (1.3–10.8) 0.37
Living donor, n (%) 56 (44.1) 39 (30.0) 50 (38.8) 0.06
Pre-emptive transplant, n (%) 33 (26.0) 22 (16.9) 22 (17.1) 0.12
Dialysis duration, months 34.5 (11.0–63.0) 47.0 (14.0–60.5) 37.0 (22.5–58.5) 0.81
Age donor, years 42.7 ± 15.5 44.7 ± 15.6 45.5 ± 14.4 0.33
Renal allograft function
Serum creatinine, µmol/L 124.0 (98.0–175.0) 123.0 (99.8–154.5) 134.0 (104.0–180.5) 0.23
eGFR, ml/min per 1.73 m2 50.1 ± 21.1 52.8 ± 19.3 50.1 ± 18.2 0.44
Proteinuria, n (%) 28 (22.0) 28 (21.5) 26 (20.2) 0.92
Glucose homeostasis
Plasma glucose (mmol/L) 5.1 (4.6–5.5) 5.1 (4.7–5.4) 5.0 (4.7–5.6) 1.00
HbA1c (%) 5.6 ± 0.3 5.6 ± 0.4 5.7 ± 0.4 0.10
Lipids and lipoproteins
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Table 2. Cont.
Tertile 1 (n = 127) Tertile 2 (n = 130) Tertile 3 (n = 129) P-Value
Total cholesterol, mmol/L 5.2 ± 1.0 5.1 ± 1.1 5.2 ± 1.3 0.62
HDL-cholesterol, mmol/L 1.5 ± 0.5 1.4 ± 0.4 1.3 ± 0.4 <0.001
LDL-cholesterol, mmol/L 3.0 ± 0.8 3.0 ± 1.0 3.1 ± 1.0 0.43
Triglycerides, mmol/L 1.6 (1.2–2.1) 1.6 (1.2–2.2) 1.7 (1.3–2.4) 0.19
Medication
Calcineurin inhibitor, n (%) 0.57
Cyclosporine 53 (41.7) 54 (41.5) 50 (38.8)
Tacrolimus 19 (15.0) 19 (14.6) 28 (21.7)
Trough level cyclosporine (µg/L) 112.0 (78.3–143.3) 102.0 (74.8–141.5) 105.0 (74.5–156.5) 0.85
Trough level tacrolimus (µg/L) 5.5 (3.9–8.0) 7.7 (6.0–9.7) 7.4 (6.0–9.6) 0.08
Proliferation inhibitor, n (%) 0.04
Azathioprine 34 (26.8) 25 (19.2) 19 (14.7)
Mycofenol 71 (55.9) 84 (64.6) 96 (74.4)
Prednisolone, n (%) 127 (100.0) 128 (98.5) 127 (98.4) 0.37
Prednisolone dose, mg/24h 10.0 (7.5–10.0) 10.0 (7.5–10.0) 10.0 (7.5–10.0) 0.19
Antihypertensive drugs, n (%) 107 (84.3) 117 (90.0) 117 (90.7) 0.21
Statins, n (%) 53 (41.7) 66 (50.8) 67 (51.9) 0.20
Amino acids
Total BCAA, µM 297.1 ± 33.7 366.6 ± 20.4 467.9 ± 64.7 <0.001
Valine, µM 159.1 ± 20.7 194.5 ± 18.4 240.5 ± 35.3 <0.001
Leucine, µM 107.6 ± 21.5 133.3 ± 17.3 168.2 ± 29.3 <0.001
Isoleucine, µM 31.6 ± 10.0 39.1 ± 11.2 59.1 ± 18.0 <0.001
Data are represented as mean ± SD, median (interquartile range) or n (%). Differences were tested by analysis of variance or Kruskal–Wallis for continuous variables and with χ 2-test for
categorical variables. SBP, systolic blood pressure; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HbA1c, hemoglobin A1c; LP-IR, lipoprotein insulin resistance
index; HDL, high-density lipoprotein; LDL, low-density lipoprotein; BCAA, branched-chain amino acids.
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3.3. BCAAs and Risk of Developing PTDM
In the subgroup of non-diabetic renal transplant recipients at baseline (n = 386) during a median
follow-up of 5.3 (IQR, 4.2–6.0) y, 38 (9.8%) subjects developed PTDM. Of the renal transplant recipients
in the highest tertile of total BCAA 17.3% developed PTDM versus 8.0% in the lowest two tertiles
(p = 0.02). The Kaplan–Meier curves for the development of PTDM according to the highest tertile
versus the two lowest tertiles of total BCAA is shown in Figure 1.
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Figure 1. Kaplan–Meier curves for the development of post-transplant diabetes mellitus (PTDM)
according to the highest tertile versus the two lowest tertile of total branched chain amino acids (BCAA)
in renal transplant recipients.
Cox regression analyses with total BCAA per standard deviation (SD) as continuous variable
showed that higher total BCAA was associated with a higher risk of developing PTDM (HR: 1.43, 95% CI
1.08–1.89, p = 0.01), independent of age and sex (Table 3, model 1). After adjustment for other potential
confounders, including renal function parameters, lipids, dietary and lifestyle factors, and use of
medication the association did not materially change (Table 3, model 2–6). In additional Cox regression
analyses with total BCAA divided in the highest tertile versus the two lower tertiles, total BCAA was
again significantly associated with development of PTDM, independent of age and sex (HR: 2.07; 95%
CI 1.07–3.99, p = 0.03). Further adjustment for potential confounders did not change the association
(Table 3, model 2–6). To illustrate the association of total BCAA with development of PTDM, an age and
sex adjusted penalized spline is shown in Figure 2. We found no significant effect modification by age
(pinteraction = 0.75), gender (pinteraction = 0.17), BMI (pinteraction = 0.31), and eGFR (pinteraction = 0.50) in the
association of total BCAA per SD with PTDM, but we did for HbA1c (pinteraction = 0.02). We continued
with stratified analyses (Supplementary Figure S2). BCAAs were associated with PTDM in renal
transplant recipients without prediabetes (HbA1c < 5.7%), but not in renal transplant recipients with
prediabetes (HbA1c ≥ 5.7%), independent of age, sex, eGFR, proteinuria, and time since transplantation.
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Table 3. Association of plasma BCAAs with post-transplant diabetes mellitus in renal transplant
recipients (n = 386).
Per SD as Continuous Variable
(µmol/L) Highest Tertile vs. Lower Two Tertiles
BCAA
No. of events 38 19 19
HR (95% CI) P Reference HR (95% CI) P
Crude 1.43 (1.09–1.88) 0.009 1.00 2.06 (1.09–3.90) 0.03
Model 1 1.43 (1.08–1.89) 0.01 1.00 2.07 (1.07–3.99) 0.03
Model 2 1.43 (1.07–1.90) 0.02 1.00 1.97 (1.02–3.82) 0.05
Model 3 1.37 (1.03–1.84) 0.03 1.00 1.82 (0.93–3.57) 0.08
Model 4 1.42 (1.06–1.90) 0.02 1.00 1.90 (0.95–3.80) 0.07
Model 5 1.47 (1.10–1.96) 0.009 1.00 2.09 (1.05–4.17) 0.04
Model 6 1.42 (1.08–1.85) 0.01 1.00 2.12 (1.09–4.12) 0.03
Cox proportional hazards regression analyses were performed to assess the association of BCAAs with PTDM. Model
1: adjustment for age and sex; model 2: model 1 + adjustment for eGFR, proteinuria, and time since transplantation;
model 3: model 2 + adjustment for total cholesterol and triglycerides; model 4: model 2 + adjustment for total
energy intake, physical activity, and BMI; model 5: model 2 + adjustment for smoking status and alcohol intake;
model 6: model 2 + adjustment for prednisolone dose and trough levels of tacrolimus and cyclosporine;. BCAA,
branched chain amino acids; PTDM, post-transplant diabetes mellitus; eGFR, estimated glomerular filtration rate.
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Figure 2. Association between plasma branched chain amino acids (BCAA) and post-transplant diabetes
mellitus (PTDM) in 386 renal transplant recipients. Data were fit by a Cox regression model based on
penalized splines and adjusted for age and sex. The gray area represents the 95% confidence interval.
3.4. S condary Analyses
In mediation analyses, we found that HbA1c mediated 53% of the association between BCAAs
and PTDM in renal transplant recipients, whereas plasma glucose was not a significant mediator in
this association (Supplementary Table S1), after adjustment for age and sex. The results of competing
risk analyses did not materially differ from those with Cox regression for the association of total BCAA
per SD as continuous variable and development of PTDM (HR: 1.44, 95% CI 1.08–1.92, p = 0.01),
adjusted for age and sex (Table 3, model 2 for comparison). Also, the analysis with total BCAA divided
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in the highest tertile versus the two lower tertiles did not differ in the competing risk analysis (HR:
2.09, 95% CI 1.10–3.96, p = 0.02), adjusted for age and sex (Table 3, model 2 for comparison).
3.5. BCAAs and Risk of All-Cause Mortality and Death-Censored Graft Failure
In the total population of both diabetic and non-diabeticrenal transplant recipients at baseline
(n = 518), 114 (22.0%) subjects died during a median follow-up of 5.4 (IQR, 4.7–6.2) y, whereas 65
(12.5%) subjects developed graft failure during a median follow-up of 5.3 (IQR, 4.5–6.0) y. There was
no significant association between total BCAA and the individual BCAAs with all-cause mortality and
death-censored graft failure (Supplementary Table S2). We found no effect modification by diabetes
for the association of total BCAA with all-cause mortality (pinteraction = 0.22) and death-censored graft
failure (pinteraction = 0.41).
4. Discussion
In this large cross-sectional study with prospective follow-up, higher concentrations of total
BCAAs are associated with a higher risk of developing PTDM in renal transplant recipients. This
association did not change after adjustment for relevant confounders, including age, sex, renal
function parameters, lipids, dietary and lifestyle factors, and use of immunosuppressive medication.
Subsequently, this association was modified by HbA1c; total BCAAs were significantly associated with
PTDM in renal transplant recipients without prediabetes (HbA1c < 5.7%), but not in renal transplant
recipients with prediabetes (HbA1c ≥ 5.7%). Furthermore, we show that the association between total
BCAA and PTDM was mediated to a considerable extent (53%) by HbA1c. In addition, no association
of total BCAAs with all-cause mortality and death-censored graft failure in renal transplant recipients
was found.
It is known that BCAAs are elevated in subjects with prediabetes, type 2 diabetes, and obesity [22].
In this cohort, BCAA concentrations were elevated in diabetic renal transplant recipients when compared
with non-diabetic renal transplant recipients (424.6 ± 97.9 µM vs. 377.6 ± 82.5 µM, respectively),
as observed in previous studies in the general population [23,55,56]. The BCAA concentrations of the
diabetic renal transplant recipients can be compared to the BCAA concentrations of 439 ± 95 µM in
patients with type 2 diabetes mellitus in the general population [25]. The BCAA concentrations of the
non-diabetic renal transplant recipients are comparable to the mean plasma levels of 370.3 ± 88.6 µM
in a large prospective population-based cohort study [26].
BCAAs are a group of essential amino acids, comprising valine, leucine, and isoleucine, and can
only be obtained from diet. They comprise about 15–25% of total protein intake [17]. Previous studies
have shown that plasma BCAA levels are modifiable by a higher or lower consumption of protein.
Prior work showed that higher consumption of BCAAs is significantly associated with higher plasma
levels of BCAAs [57]. The correlation was moderate, but comparable to other diet-plasma biomarker
correlations. It has been shown that dietary protein reduction lowers serum levels of BCAAs [58].
Recently, a randomized controlled crossover trial even showed that short term dietary reduction of
BCAAs decreases postprandial insulin secretion [59]. It is known, that around 80% of dietary BCAAs
reach the blood circulation [60], but circulating plasma levels of BCAAs can also be affected by their
catabolism [61]. The initial site of the BCAA metabolism is skeletal muscle, because of the high
branched-chain-amino-acid aminotransferase (BCAT) activity in the muscle [62]. This metabolism
is sensitive to changes in the amount and composition of food. A high protein diet leads to higher
concentrations of BCAAs, whereas a low protein diet lowers the plasma BCAA concentrations [62,63].
Indeed, in our study, subjects in the highest tertile of total BCAA had a higher 24 h urinary urea
excretion, which is an objective measurement for total protein intake, when compared to subjects in
the lowest tertile of total BCAA.
The results of the prospective analysis with PTDM are consistent with previous studies that
reported the association of BCAAs with type 2 diabetes in the general population [21,22,64]. Recently,
we showed in a prospective cohort study that high concentrations of BCAAs are associated with
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increased risk of developing type 2 diabetes [26]. The fact that total BCAAs were significantly associated
with PTDM in subjects without prediabetes, but not in prediabetic subjects suggest that alterations
in total BCAAs might be an early signal of deterioration of glycemic control. A previous study has
shown that elevated BCAAs levels may appear long before other markers of insulin resistance become
abnormal [21]. Elevations in circulating BCAAs can occur before any alterations in insulin action are
detectable. Moreover, it has been reported that plasma BCAAs might serve as a better indicator of
impaired insulin resistance when compared to plasma glucose levels [65], since in patients without
prediabetes the metabolic status is not deteriorated enough to alter plasma glucose levels.
The secondary outcomes, all-cause mortality and death-censored graft failure, were not associated
with total BCAAs. This is in contrast to a previous study that showed an inverse association of total
BCAAs and death in patients at risk for coronary artery disease [33], supporting the underlying
malnutrition-inflammation syndrome hypothesis. Furthermore, the large Estonian biobank study
also observed inverse associations between BCAAs and all-cause mortality [34]. Moreover, in the
ADVANCE study including individuals with type 2 diabetes, low levels of leucine and valine were
associated with increased all-cause mortality [35]. In our study 114/518 (22.0%) renal transplant
recipients died during a median follow-up of 5.4 years, resulting in a death rate of 4.1% per year,
which is slightly higher when compared to the FAVORIT trial, a large multi-center double-blind
randomized controlled trial in 4110 stable renal transplant recipients (age 52 ± 9.4 years, 62.8% male at
5 years after transplantation) in which 493/4110 (12.0%) subjects died within 4.0 years of follow-up,
resulting in a death rate of 3.0% per year [66]. Prior work showed that levels of valine and leucine,
but not isoleucine, were significantly lower in patients with stage I and II chronic kidney disease,
when compared with controls [37], suggesting potential use as a biomarker for renal dysfunction.
Currently, there are several potential mechanisms that could explain the contribution of BCAAs
to the development of insulin resistance, type 2 diabetes, and PTDM, although these mechanisms are
not completely understood. One mechanism proposes that BCAAs interfere with insulin signaling
through activation of the mammalian target of rapamycin complex 1 (mTORC1) in skeletal muscle
and serine phosphorylation of insulin receptor substrate 1 and 2, which promotes insulin resistance
and can lead to the development of type 2 diabetes [20]. However, conflicting results regarding the
role of BCAAs to elicit insulin resistance have been reported [67] and do question whether mTORC1
activation is sufficient or necessary in the development of insulin resistance. Others assume that BCAA
dysmetabolism, especially in obesity, contributes to a rise in BCAAs, which results in accumulation of
potential toxic BCAA metabolites, which could induce cellular damage [20]. These BCAA metabolites
might lead to mitochondrial dysfunction and β-cell apoptosis, which is common in insulin resistance
and type 2 diabetes [20]. Nevertheless, the association of total BCAAs and PTDM in our study was
independent of BMI. Moreover, a previous study in the general population showed that the association
of BCAAs with insulin resistance was independent of leptin and adiponectin, both valid biomarkers of
adipose tissue dysfunction, when taking BMI into account [25], suggesting the association is presumably
mainly driven by another mechanism.
To the best of our knowledge, this is the first study that studied the association of BCAAs
with the development of PTDM in renal transplant recipients. Strengths of this study include the
complete follow-up and use of clinical endpoints (PTDM, all-cause mortality, and death-censored
graft failure), which are relevant in daily clinical practice. Furthermore, this study had a considerable
follow-up period. Another strength is the use of stable patients who had a functioning graft for at
least 1 year, which resulted in exclusion of patients with transient hyperglycemia post-transplantation,
which occurs frequently and is evident in about 90% of renal transplant recipients in the first few weeks
post-transplantation [68,69]. Hyperglycemia can also occur as a result of rejection therapy, infections,
and other critical conditions [46]. Therefore, it is important to diagnose PTDM in stable patients
(i.e., on maintenance immunosuppression, stable renal function and in absence of acute infections) [46].
This study also has several limitations. First, it is a single-center study, with a study population
mainly consisting of Caucasians. As ethnicity is an independent risk factor for developing PTDM [5],
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it is important to repeat this study in more diverse populations. Renal transplant recipients in the
current study were included at a median of 5.0 years after transplantation. Therefore, extrapolating
our results to patients in early stages after renal transplantation should be done with caution. The
clinical significance or impact of the diagnosis of PTDM early or late after transplantation has yet to be
determined [16]. In addition, age at time of transplantation in our cohort is lower when compared
to other European cohorts [70]. Moreover, the prevalence of living donor grafts is higher in the
Netherlands [71], which might also contribute to a lower age in our cohort, since younger subjects
have a broader social network and therefore likely a higher chance of finding a compatible living
donor at younger age. Furthermore, it is known that oral glucose tolerance tests (OGTTs) are the gold
standard diagnostic tool to diagnose PTDM. Unfortunately, OGTTs were not performed, but recently
it has been shown that the combined use of fasting plasma glucose and HbA1c criteria appears to
be a diagnostic strategy for PTDM in stable renal transplant recipients [72]. Another limitation of
this study is that only 38 subjects developed PTDM during follow-up, which led to a lack of power.
Unfortunately, a comorbidity index was not available in our cohort and we do not have data on weight
gain post-transplantation. It cannot be excluded that change of weight could serve as a source of bias
and could spuriously strengthen or weaken the association of BCAAs with development of PTDM.
Finally, longer-term intervention studies are required to determine whether BCAAs are causally related
to the development of diabetes mellitus or merely act as markers of underlying pathophysiology.
5. Conclusions
In conclusion, this single-center cross-sectional assessment of BCAA in stable renal transplant
recipients showed that high plasma concentrations of total BCAA are associated with a higher risk
of developing PTDM during prospective follow-up. Alterations in BCAA levels might be an early
signal of deterioration of glycemic control in renal transplant recipients. Further research is needed to
investigate the possible mechanism/role of BCAAs in the development of post-transplant diabetes.
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